OTCMKTS:PHGUF Pharming Group (PHGUF) Stock Price, News & Analysis → Are you prepared for a Chinese 'invasion?' (From Behind the Markets) (Ad) Free PHGUF Stock Alerts $0.93 0.00 (0.00%) (As of 06/14/2024) Add Compare Share Share Today's Range$0.93▼$0.9350-Day Range$0.91▼$1.2052-Week Range$0.90▼$1.40VolumeN/AAverage Volume200 shsMarket Capitalization$605.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest Get Pharming Group alerts: Email Address Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About Pharming Group Stock (OTCMKTS:PHGUF)Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.Read More PHGUF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHGUF Stock News HeadlinesMay 21, 2024 | finance.yahoo.comPharming Group reports on results of the 2024 Annual General Meeting of ShareholdersMay 8, 2024 | bizjournals.comOrchard to lose out on milestone payments as Pharming Group ends collabApril 28, 2024 | wsj.comPharming Group N.V.April 19, 2024 | finance.yahoo.comPharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025April 18, 2024 | finance.yahoo.comPharming Group announces the placement of €100 million convertible bonds due 2029April 8, 2024 | markets.businessinsider.comOptimistic Buy Rating on Pharming Group Backed by Promising Leniolisib Trials and Strategic Market ExpansionApril 8, 2024 | finanznachrichten.dePharming Group N.V.: Pharming announces completion of enrollment in pediatric clinical trial of leniolisibApril 4, 2024 | finance.yahoo.comPharming Group announces the 2024 Annual General Meeting of ShareholdersApril 3, 2024 | finance.yahoo.comPharming Group to participate in April investor conferencesMarch 17, 2024 | finance.yahoo.comPharming Group N.V. (AMS:PHARM) Analysts Are Pretty Bullish On The Stock After Recent ResultsMarch 16, 2024 | finance.yahoo.comPharming Group Full Year 2023 Earnings: US$0.015 loss per share (vs US$0.021 profit in FY 2022)March 15, 2024 | markets.businessinsider.comPharming Group’s Strong Financial Performance and Growth Potential Merit Buy RatingFebruary 29, 2024 | finance.yahoo.comPharming Group to report fourth quarter and full year 2023 financial results on March 14February 20, 2024 | uk.investing.comPharming Group NV (PHAR)January 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG) and Pharming Group (OtherPHGUF)January 8, 2024 | finanznachrichten.dePharming Group N.V.: Pharming Group announces updated full year 2023 guidance and Joenja U.S. launch updateJanuary 8, 2024 | markets.businessinsider.comPharming Group Projects 2023 Total Revenues To Rise 19%January 8, 2024 | finance.yahoo.comPharming Group announces updated full year 2023 guidance and Joenja® U.S. launch updateNovember 21, 2023 | finance.yahoo.comPharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisibNovember 10, 2023 | finance.yahoo.comPharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approvalNovember 7, 2023 | finance.yahoo.comPharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific MeetingOctober 26, 2023 | msn.comPharming GAAP EPS of $0.01 beats by $0.005, revenue of $66.7M beats by $4.87MOctober 12, 2023 | finanznachrichten.dePharming Group N.V.: Pharming Group to report third quarter 2023 financial results on October 26October 12, 2023 | finance.yahoo.comPharming Group to report third quarter 2023 financial results on October 26September 22, 2023 | finance.yahoo.comPharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?See More Headlines Receive PHGUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:PHGUF Previous SymbolOTC:PHGUF CUSIPN/A CIKN/A Webwww.pharming.com Phone(171) 524-7400Fax31-0-71-524-7445Employees332Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,550,000.00 Net Margins-4.00% Pretax Margin-4.90% Return on Equity-4.54% Return on Assets-2.15% Debt Debt-to-Equity Ratio0.14 Current Ratio1.43 Quick Ratio1.16 Sales & Book Value Annual Sales$245.32 million Price / Sales2.47 Cash Flow$0.01 per share Price / Cash Flow92.64 Book Value$0.34 per share Price / Book2.73Miscellaneous Outstanding Shares652,410,000Free FloatN/AMarket Cap$605.83 million OptionableNot Optionable Beta1.11 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Sijmen de Vries M.B.A. (Age 65)M.D., President, CEO & Executive Director Comp: $1.18MMr. Jeroen Wakkerman (Age 55)Chief Financial Officer Ms. Mireille Sanders M.Sc. (Age 56)Chief Operations Officer Susanne EmbletonInvestor Relations ManagerMr. Ruud Van Outersterp (Age 60)Chief Ethics & Compliance Officer Dr. Anurag Relan M.D. (Age 52)MPH, Chief Medical Officer Mr. Stephen Toor (Age 53)Chief Commercial Officer & GM Americas Dr. Alexander Breidenbach M.B.A.Chief Business OfficerDr. Bruno M. L. Giannetti (Age 72)Consultant More ExecutivesKey CompetitorsStructure TherapeuticsNASDAQ:GPCRIndiviorNASDAQ:INDVBausch Health CompaniesNYSE:BHCDeciphera PharmaceuticalsNASDAQ:DCPHJanux TherapeuticsNASDAQ:JANXView All Competitors PHGUF Stock Analysis - Frequently Asked Questions How have PHGUF shares performed in 2024? Pharming Group's stock was trading at $1.1750 at the start of the year. Since then, PHGUF stock has decreased by 21.0% and is now trading at $0.9286. View the best growth stocks for 2024 here. Are investors shorting Pharming Group? Pharming Group saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 5,830,500 shares, an increase of 23.7% from the April 30th total of 4,713,600 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days. View Pharming Group's Short Interest. How were Pharming Group's earnings last quarter? Pharming Group (OTCMKTS:PHGUF) released its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.02) earnings per share for the quarter. The biotechnology company earned $55.59 million during the quarter. Pharming Group had a negative net margin of 4.00% and a negative trailing twelve-month return on equity of 4.54%. How do I buy shares of Pharming Group? Shares of PHGUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PHGUF) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.